Skip to main content
. Author manuscript; available in PMC: 2011 May 1.
Published in final edited form as: Clin Cancer Res. 2010 Apr 20;16(9):2591–2604. doi: 10.1158/1078-0432.CCR-09-2443

Fig 5.

Fig 5

Doxorubicin and TRAIL combination inhibits STS associated angiogenesis. A) CD31 immunohistochemisty and CD31/TUNEL double immunoflorescence (CD31 = red, TUNEL = green) demonstrate decrease in blood vessel density in combination treatment samples but no evidence of endothelial cell apoptosis; B) Angiogenesis RT PCR array demonstrated a significant increase in CXCL10 mRNA expression and a marked decrease in IL8 mRNA levels in combination treated tumor samples of both STS xenograft models; C) Effects of treatment on CXCL10 and IL8 mRNA expression was further confirmed via RT PCR using an independent cohort of tumor samples (*p<0.05). No significant gene expression changes were noticed in samples treated with either agent alone; D) effect of treatment on IL8 (red) and CXCL10 (red) protein expression in vivo was evaluated by immunoflorescence (nuclei = blue). An increase in tumor infiltrating macrophages and a decrease in tumor infiltrating neutrophils was also observed in TRAIL/doxorubicin treated tumors. Graphs represent the average of three repeated experiments ±SD.